Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report published on Tuesday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Stock Down 14.0 %

CTXR stock opened at $1.85 on Tuesday. The stock’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $8.18. Citius Pharmaceuticals has a 12-month low of $1.47 and a 12-month high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). As a group, equities research analysts anticipate that Citius Pharmaceuticals will post -4.5 earnings per share for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Citius Pharmaceuticals by 14.1% in the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after buying an additional 232,656 shares during the last quarter. Chelsea Counsel Co. boosted its stake in shares of Citius Pharmaceuticals by 9.8% during the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after acquiring an additional 25,000 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in shares of Citius Pharmaceuticals by 33.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after acquiring an additional 50,000 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Citius Pharmaceuticals during the 3rd quarter valued at $50,000. Finally, Miller Investment Management LP increased its stake in shares of Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares in the last quarter. 16.88% of the stock is currently owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.